Clomiphene 50 mg (Generic)

Product Overview

Clomiphene 50 mg is a widely prescribed oral medication for the treatment of female infertility linked to ovulatory dysfunction. Produced by HAB Pharmaceuticals & Research Ltd, each strip contains ten film‑coated tablets delivering a precise 50 mg dose of clomiphene citrate. The product is offered in multiple pack configurations — 100, 200, and 300 tablets — to support varied treatment protocols and patient needs. Shipping timelines typically range from six to fifteen days, depending on the destination and customs processing. This generic formulation meets the same quality standards as the branded counterpart, providing an affordable option for clinicians and patients seeking effective ovulation induction. The medication is indicated for women who experience irregular or absent menstrual cycles, and it is often incorporated into comprehensive fertility management plans that may include lifestyle modification, nutritional support, and assisted reproductive techniques. Real‑world clinical experience has demonstrated consistent ovulation rates and favorable pregnancy outcomes when the drug is used according to evidence‑based guidelines.

What is Clomiphene 50 mg

Clomiphene citrate belongs to the class of non‑steroidal selective estrogen receptor modulators (SERMs). The 50 mg tablet delivers a standardized dose of the active ingredient, which acts primarily as an estrogen receptor antagonist in the hypothalamic region. By blocking estrogen feedback, clomiphene stimulates the release of gonadotropin‑releasing hormone (GnRH) from the hypothalamus, which in turn prompts the anterior pituitary to increase secretion of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). This hormonal surge promotes the development of multiple ovarian follicles and prepares the endometrium for potential implantation. The drug’s partial agonist activity at certain receptor sites allows for sustained use without complete receptor down‑regulation, making it suitable for repeated treatment cycles. Clinically, clomiphene has been employed for more than five decades, and its mechanism remains a cornerstone of ovulation induction therapy in contemporary reproductive medicine.

Uses and Benefits

The primary therapeutic use of clomiphene 50 mg is the management of anovulatory or oligo‑ovulatory cycles in women diagnosed with polycystic ovary syndrome (PCOS), idiopathic infertility, or other endocrine disorders that impair follicular development. When administered according to established protocols, clomiphene restores ovulation in roughly 70 % of appropriately selected patients and increases the cumulative pregnancy rate to approximately 10‑15 % within six treatment cycles. Beyond its ovulation‑inducing properties, the medication offers several practical advantages: it is administered orally, requires no invasive procedures, and is relatively inexpensive compared with injectable gonadotropins or in‑vitro fertilization (IVF). Moreover, the drug’s well‑characterized pharmacokinetics and safety profile enable clinicians to tailor dosing regimens to individual patient characteristics, such as age, body mass index, and prior response to therapy. For more detailed information, see the MedlinePlus drug entry. Evidence from systematic reviews and meta‑analyses supports its role as a first‑line agent in fertility treatment algorithms, especially when cost and accessibility are significant considerations.

How It Works

The pharmacodynamic action of clomiphene 50 mg centers on its antagonism of estrogen receptors located in the arcuate nucleus of the hypothalamus. This blockade prevents estrogen‑mediated negative feedback, effectively simulating a low‑estrogen environment. In response, the hypothalamus escalates GnRH pulse frequency, which stimulates the anterior pituitary to secrete increased amounts of FSH and LH. Elevated FSH promotes the recruitment and maturation of multiple ovarian follicles, while the LH surge triggers the final maturation step that leads to ovulation approximately 36‑48 hours after the final tablet is taken. The drug’s partial agonist activity at some estrogen receptor subtypes permits continued dosing without complete receptor down‑regulation, allowing for repeated cycles. Additionally, clomiphene’s modest androgenic properties may contribute to endometrial thickening, creating a more receptive environment for implantation. The combined endocrine response creates a physiological milieu conducive to natural conception when timed with intercourse or assisted insemination.

Dosage Guidelines

The recommended dosing schedule for clomiphene 50 mg involves the oral administration of one tablet daily for five consecutive days, typically initiated on days three through five of the menstrual cycle. This timing aligns with the early follicular phase, when the hypothalamic‑pituitary axis is most responsive to GnRH stimulation. If ovulation does not occur after the first cycle, a physician may consider increasing the dose to 100 mg daily for five days in subsequent cycles, but the total number of treatment cycles should generally not exceed six to minimize the risk of ovarian hyperstimulation and to allow for evaluation of response. Throughout the treatment course, clinicians are advised to monitor follicular development using transvaginal ultrasound or to employ ovulation predictor kits to determine the optimal day for intercourse or timed intercourse. Adjustments may also be necessary for patients with hepatic impairment, advanced maternal age, or those who have previously demonstrated a poor response to clomiphene. Throughout all cycles, patients should be counseled to report any unusual symptoms and to maintain regular follow‑up appointments with their healthcare provider.

Side Effects

Like all pharmacologic agents, clomiphene 50 mg can produce adverse effects, although most are mild and self‑limited. The most frequently reported symptoms include hot flashes, breast tenderness, abdominal discomfort, and nausea, which typically resolve after the treatment cycle ends. Some users experience visual disturbances such as blurred vision, glare, or decreased visual acuity; these effects warrant immediate discontinuation and medical evaluation. In rare cases, clomiphene may precipitate ovarian hyperstimulation syndrome (OHSS), characterized by abdominal distension, pelvic pain, rapid weight gain, and, in severe instances, shortness of breath due to ascites. Additional less common reactions include headache, mood swings, and endometrial thickening, which can influence implantation outcomes. Patients should be instructed to seek prompt medical attention if they develop severe abdominal pain, shortness of breath, or signs of allergic reaction such as rash or swelling. Ongoing pharmacovigilance studies continue to monitor the long‑term safety profile of clomiphene, reinforcing its status as a well‑tolerated therapy when overseen by a qualified clinician.

Warnings and Precautions

Clomiphene 50 mg is contraindicated in individuals with known hypersensitivity to the drug, existing pregnancy, or ovarian cysts that are not directly related to polycystic ovary syndrome. The medication should be avoided in patients with significant liver dysfunction, adrenal insufficiency, or pituitary tumors, as these conditions may exacerbate hormonal imbalances. Prior to initiation, a pregnancy test is mandatory to ensure the patient is not already pregnant, and ongoing monitoring is recommended for women with a history of thromboembolic disorders or unexplained vaginal bleeding. Concomitant use with other ovulation‑inducing agents or hormonal therapies is discouraged without explicit medical supervision, as this can increase the likelihood of multiple pregnancies and OHSS. The drug should be stored at room temperature, away from moisture and direct sunlight, and kept out of reach of children. Healthcare providers are encouraged to discuss the potential risks and benefits with patients, ensuring informed consent and adherence to recommended monitoring protocols. For detailed regulatory information, refer to the U.S. Food and Drug Administration and the National Center for Biotechnology Information.

Frequently Asked Questions

1. What is the typical starting dose of clomiphene 50 mg? The usual starting dose is one 50 mg tablet taken daily for five days, beginning on cycle day three to five.
2. How long does it take for ovulation to occur after taking clomiphene? Ovulation typically occurs 36‑48 hours after the final dose, but timing can vary among individuals.
3. Can clomiphene be used by women who are already pregnant? No, clomiphene is contraindicated during pregnancy and a pregnancy test must be negative before starting therapy.
4. Is clomiphene associated with multiple pregnancies? Yes, the drug can increase the chance of twins or higher‑order multiples, so clinicians monitor follicular development closely.
5. What should I do if I miss a dose during my treatment cycle? If a dose is missed, the patient should contact their healthcare provider; generally, the missed tablet may be taken as soon as remembered if it is still within the five‑day window.

Related Products

• Tretoin 0.1% Gel (Tretinoin)
• Tretoin 0.025% Cream (Tretinoin)
• Tretoin 0.05% Cream (Tretinoin)
• Tretinex Cream (Tretinoin)
• Tretoin Cream (Tretinoin)
• Naltrexone 50 mg (Naltrexone)
• Methylprednisolone (Signapred 4 mg)
• Signapred 4 mg (Methylprednisolone)
• Griseofulvin 500 mg (Generic)
• Lamifil 250 Mg (Terbinafine)
• Fungicyte 150 (Fluconazole 150mg)
• Dermozole 500 mg (Griseofulvin)